CEO Marc Gleeson (Azura)
October 22, 2020 08:05 AM EDT
Financing

Azu­ra Oph­thalmics gets a $20M boost for its R&D work on eye dis­eases

Nicole DeFeudis

Editor

Three years af­ter clos­ing a $16 mil­lion Se­ries B, the same group of in­vestors are back to give Azu­ra Oph­thalmics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times